chlorambucil has been researched along with pci 32765 in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (56.52) | 24.3611 |
| 2020's | 10 (43.48) | 2.80 |
| Authors | Studies |
|---|---|
| Byrd, JC; Flynn, JM; Johnson, AJ; Jones, JJ; Woyach, JA | 1 |
| Assaily, W; Bence-Bruckler, I; Chamakhi, I; Christofides, A; Owen, C; Robinson, S; Toze, C | 1 |
| Bairey, O; Barr, PM; Bartlett, NL; Burger, JA; Cheng, M; Clow, F; Coutre, S; Devereux, S; Gaidano, G; Ghia, P; Grosicki, S; Hellmann, A; Hillmen, P; James, DF; Janssens, A; Kipps, TJ; Li, J; Maslyak, Z; Mayer, J; McCarthy, H; O'Dwyer, M; Offner, F; Owen, C; Polliack, A; Quach, H; Robak, T; Schuh, A; Siddiqi, T; Simpson, D; Stevens, DA; Styles, L; Suri, D; Tam, CS; Tedeschi, A | 1 |
| Baculea, S; Cote, S; Diels, J; Van Sanden, S | 1 |
| Baculea, S; Cote, S; Mealing, S; Singh, M; Whelan, J | 1 |
| Bairey, O; Barr, PM; Burger, J; Coutre, S; James, DF; Kipps, TJ; Owen, C; Robak, T; Styles, L; Tedeschi, A; Zhou, C | 1 |
| Redekop, WK; Sinha, R | 1 |
| Barr, PM; Burger, JA; Chang, S; Coutre, S; Cramer, P; Dilhuydy, MS; Fraser, G; Graef, T; Hess, G; Hillmen, P; Howes, A; James, DF; Liu, E; Moreno, C; O'Brien, S; Patel, K; Styles, L; Tedeschi, A; Valentino, R; Vermeulen, J | 1 |
| Jain, N | 1 |
| Anz, B; Ben-Yehuda, D; Clow, F; Demirkan, F; Flinn, IW; Gill, D; Greil, R; Gribben, JG; Hsu, E; James, DF; Larratt, L; Lih, CJ; Moreno, C; Novak, J; Samoilova, O; Simkovic, M; Strugov, V; Styles, L; Tedeschi, A; Zhou, C | 1 |
| Romero, D | 1 |
| Anz, B; Bairey, O; Barr, PM; Burger, JA; Demirkan, F; Fedorov, V; Flinn, IW; Gaidano, G; Gill, D; Greil, R; Gribben, JG; Kipps, TJ; Lin, J; Moreno, C; Robak, T; Simpson, D; Stevens, D; Styles, L; Tedeschi, A; Webb, T | 1 |
| Bairey, O; Barr, PM; Burger, JA; Coutre, SE; Dai, S; Dean, JP; Devereux, S; Ghia, P; Grosicki, S; Hillmen, P; Kipps, TJ; Lal, I; McCarthy, H; Moreno, C; Offner, F; Owen, C; Robak, T; Simpson, D; Tedeschi, A | 1 |
| Andreadis, C; Fakhri, B | 1 |
| Gao, A; Gao, W; Huo, D; Ran, X; Sheng, Z; Song, S; Yu, M; Zhu, H | 1 |
| Barrientos, JC; Blum, LK; Burger, JA; Byrd, JC; Dean, JP; Hillmen, P; Hoh, HY; Kay, NE; Kipps, TJ; Lal, ID; Mongan, A; Mulligan, SP; O'Brien, S; Solman, IG | 1 |
| Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM | 1 |
| Anz, B; Cheung, LWK; Demirkan, F; Flinn, IW; Gill, D; Greil, R; Gribben, JG; Larratt, L; Moreno, C; Nguyen, AN; Simkovic, M; Styles, L; Tedeschi, A; Wang, Z; Zhou, C | 1 |
| Anz, B; Dai, S; Dean, JP; Demirkan, F; Flinn, IW; Gill, D; Greil, R; Gribben, JG; Hsu, E; Kwei, K; Larratt, L; Moreno, C; Novak, J; Simkovic, M; Strugov, V; Tedeschi, A | 1 |
| Bairey, O; Barr, PM; Burger, JA; Coutre, SE; Dearden, C; Ghia, P; Grosicki, S; Hillmen, P; Hsu, E; Kipps, TJ; Li, JY; McCarthy, H; Moreno, C; Offner, F; Owen, C; Robak, T; Szoke, A; Tedeschi, A; Zhou, C | 1 |
| Baeten, K; Benjamini, O; Caces, DB; Follows, G; Howes, A; Janssens, A; Kater, AP; Levin, MD; Moreno, C; Munir, T; Niemann, CU; Osterborg, A; Owen, C; Parisi, L; Qi, K; Qi, Q; Robak, T; Schuier, N; Simkovic, M; Srinivasan, S; Stevens, D; Voloshin, S; Vorobyev, V; Yagci, M; Ysebaert, L | 1 |
| Baeten, K; Benjamini, O; Caces, DB; Follows, GA; Howes, A; Janssens, A; Kater, AP; Levin, MD; Moreno, C; Munir, T; Niemann, CU; Owen, C; Parisi, L; Qi, K; Qi, Q; Robak, T; Schuier, N; Simkovic, M; Sinet, P; Srinivasan, S; Voloshin, S; Vorobyev, V; Yagci, M; Ysebaert, L | 1 |
4 review(s) available for chlorambucil and pci 32765
| Article | Year |
|---|---|
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Piperidines; Practice Patterns, Physicians'; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Vidarabine | 2014 |
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Canada; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2015 |
Selecting Frontline Therapy for CLL in 2018.
Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Smith-Magenis Syndrome; Vidarabine | 2018 |
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Prospective Studies; Pyrazines; Sulfonamides | 2020 |
10 trial(s) available for chlorambucil and pci 32765
| Article | Year |
|---|---|
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neutropenia; Piperidines; Pyrazoles; Pyrimidines; Survival Analysis | 2015 |
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Patient Safety; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Survival Rate | 2018 |
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
A cross-trial comparison of single-agent ibrutinib
Topics: Adenine; Antibodies, Monoclonal, Humanized; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2020 |
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
Topics: Adenine; Aged; Aged, 80 and over; Chlorambucil; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Patient Safety; Piperidines; Prognosis; Progression-Free Survival; Pyrazoles; Pyrimidines; Risk; Treatment Outcome | 2020 |
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chlorambucil; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Natural Killer T-Cells; Neoplasm Recurrence, Local; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Salvage Therapy; T-Lymphocytes, Regulatory | 2020 |
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cytokines; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Premedication; Prospective Studies | 2021 |
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2022 |
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Topics: Adenine; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome | 2022 |
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pneumonia | 2023 |
9 other study(ies) available for chlorambucil and pci 32765
| Article | Year |
|---|---|
Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bayes Theorem; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pyrazoles; Pyrimidines; Vidarabine | 2017 |
Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Health Resources; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Econometric; Piperidines; Pyrazoles; Pyrimidines; Quality-Adjusted Life Years; Rituximab; Survival Analysis | 2017 |
Survival adjusting for crossover: phase 3 study of ibrutinib
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials, Phase III as Topic; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2018 |
Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
Topics: Adenine; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chlorambucil; Comorbidity; Cost-Benefit Analysis; Drug Therapy; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Markov Chains; Neutropenia; Outcome Assessment, Health Care; Piperidines; Pyrazoles; Pyrimidines; Quality-Adjusted Life Years; United Kingdom | 2018 |
Alliance to iLLUMINATE the chemo-free sign.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Professional-Patient Relations; Progression-Free Survival; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2019 |
Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab | 2019 |
CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Clinical Trials, Phase III as Topic; Frail Elderly; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Survival Rate; Treatment Outcome | 2019 |
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Progression-Free Survival | 2023 |